Spike Protein Peptides for Durable Follicular Helper T Cell Induction

The patent introduces follicular helper T cells (Tfh cells) as an intermediary component to bridge the gap between initial antibody production and long-term maintenance. These Tfh cells act as mediators that provide sustained signals to B cells in germinal centers, enabling continuous antibody production and memory B cell formation, thereby extending the duration of humoral immunity beyond what mRNA vaccines alone can achieve.

The invention creates a composite immune response system that combines multiple cell types (mRNA-transfected antigen-presenting cells, follicular helper T cells, and B cells) working together. This composite approach integrates different immune mechanisms - antigen presentation, T cell help, and B cell antibody production - to achieve both strong initial responses and sustained long-term immunity that neither component could achieve alone.

The patent segments the immune response into distinct functional components: antigen-presenting cells that process and present spike protein antigens, follicular helper T cells that provide sustained help signals, and B cells that produce antibodies. By segmenting and optimizing each component's function, particularly enhancing Tfh cell responses through specific mRNA vaccine design, the system achieves both strong neutralizing antibodies and durable memory T cell persistence.

The vaccine performs preliminary action by pre-activating and directing follicular helper T cell responses during the initial vaccination phases. This preliminary Tfh cell activation establishes a foundation of durable memory T cells before potential variant exposures occur, ensuring long-term cellular immunity durability that can withstand time passage and variant evolution.

The patent extracts and isolates specific Tfh-inducing peptide sequences from the complex SARS-CoV-2 spike protein antigen. By taking out these critical peptide epitopes that specifically activate follicular helper T cells, the invention simplifies the vaccine composition from complex peptide pools to defined protective epitopes, reducing analytical and manufacturing complexity while maintaining effective T cell activation.

The invention applies local quality by focusing immune activation on specific critical regions (epitopes) of the spike protein that are most effective at inducing Tfh cells, rather than using the entire protein or uniform peptide pools. This localized approach concentrates immunogenicity in high-value regions, improving T cell activation efficiency while simplifying vaccine design and analysis compared to comprehensive peptide coverage.